可视化热敏变色个性化补偿物在乳腺癌改良根治术后放疗中的剂量学分析
结果显示热敏变色补偿物皮肤贴合性更好、气腔体积显著更小(3833 mm³ vs 21498 mm³),剂量学性能与虚拟补偿物计划一致,目标覆盖和OAR保护不受影响,未增加皮肤毒性。
要点
- 热敏变色个性化补偿物较商用补偿物显著减少气腔体积(3833 mm³ vs 21498 mm³)。
- 商用补偿物组真实计划目标覆盖率显著降低(89.9% vs 95%),均匀性(0.153 vs 0.136)和适形性(0.817 vs 0.810)变差。
- 热敏变色补偿物组虚拟与真实计划间OAR剂量和目标指标无显著差异,皮肤毒性均为I级。
核心结论
- 可视化热敏变色个性化补偿物皮肤贴合性更优、气腔更小、位置重复性更好,剂量学性能与虚拟补偿物计划一致,支持其在PMRT中的临床应用。
主要发现
- A组虚拟计划(A1)与真实计划(A2)在OAR剂量(如患侧肺、心脏、对侧乳腺、皮肤Dmax/Dmean)及靶区指标(V50Gy、Dmax、HI、CI、MU)上无显著差异。
- A3计划(A1应用于热敏补偿物治疗)较A1计划在靶区覆盖率(94.05% vs 95.14%)、HI(0.148 vs 0.147)和CI(0.83 vs 0.84)上有微小差异。
- B组真实计划(B2)较虚拟计划(B1)显著降低靶区覆盖率(89.9% vs 95%),均匀性(0.153 vs 0.136)和适形性(0.817 vs 0.810)变差,归因于商用补偿物产生的气隙。
- 热敏变色个性化补偿物皮肤贴合性更好,气腔体积显著小于商用补偿物(3833 mm³ vs 21498 mm³)。
- 所有患者皮肤毒性均为I级,组间无差异。
关键数值与推荐
- 热敏变色个性化补偿物气腔体积3833 mm³ vs 商用补偿物21498 mm³。
- B组真实计划靶区覆盖率89.9% vs 虚拟计划95%,均匀性0.153 vs 0.136,适形性0.817 vs 0.810。
- A3计划靶区覆盖率94.05% vs A1计划95.14%,HI 0.148 vs 0.147,CI 0.83 vs 0.84。
临床怎么用
- 热敏变色个性化补偿物可用于PMRT,其剂量学性能与虚拟补偿物计划一致,且不增加皮肤毒性。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To explore the feasibility and advantages of the visualized thermosensitive color-changing personalized bolus in post-mastectomy radiotherapy (PMRT). MATERIALS AND METHODS: Forty PMRT patients (June 2023-June 2024) were randomized into two groups. Group A (experimental group, 20 patients) underwent two CT scans: A1 (without compensator) and A2 (with the visualized thermosensitive color-changing personalized bolus), followed by treatment with the thermosensitive color-changing personalized bolus. Group B (control group, 20 patients) also underwent two CT scans: B1 (without bolus) and B2 (with a conventional commercial bolus), followed by treatment with the commercial bolus. Treatment plans were generated for virtual bolus (A1-Plan, B1-Plan) and real bolus (A2-Plan, B2-Plan). A3-Plan (A1-Plan applied to thermosensitive bolus treatment) and B2-Plan (B1-Plan applied to commercial bolus treatment) were compared to evaluate dosimetric differences in target volumes, organs at risk (OARs), and skin toxicity. RESULTS: In Group A, A1-Plan and A2-Plan showed no significant differences in OAR doses (e.g., ipsilateral lung, heart, contralateral breast, skin Dmax/Dmean) or target metrics (V50Gy, Dmax, homogeneity index (HI), conformity index (CI), monitor units (MU)). A3-Plan compared to A1-Plan had minor differences in target coverage (94.05% vs. 95.14%), HI (0.148 vs. 0.147), and CI (0.83 vs. 0.84). In Group B, B2-Plan had significantly reduced target coverage (89.9% vs. 95%), homogeneity (0.153 vs. 0.136), and conformity (0.817 vs. 0.810) compared to B1-Plan, attributed to air gaps from the commercial bolus. The thermosensitive color-changing personalized bolus had better skin adherence, significantly reduced air cavity volumes (3833 mm³ vs. 21498 mm³), and maintained equivalent dosimetric performance to virtual boluses. Skin toxicity was Grade I in all patients without differences between groups. CONCLUSIONS: The visualized thermosensitive color-changing personalized bolus demonstrated superior skin adherence, smaller air gaps, and better positional reproducibility compared to commercial boluses. Its dosimetric performance was consistent with virtual bolus plans, ensuring target coverage and OAR protection without increased skin toxicity. These findings support its clinical application in PMRT.
引用
- Wang Y, Huang F, Han W, et al. Innovative applications of visualized thermosensitive color-changing personalized boluses in post-mastectomy radiotherapy: a dosimetric analysis. Radiat Oncol. 2025. PMID: 40149020. doi:10.1186/s13014-025-02625-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。